---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-027263"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:45:21.657084+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Reviva Q3 net loss $3.5M; cash $23.2M; Phase 3 enrollment >30%, topline mid-2023

## Summary
- Net loss of $3.5M ($0.18 per share) for Q3 2022 vs $2.3M ($0.12) in Q3 2021.
- Cash $23.2M as of Sep 30, 2022, down from $29.7M at Dec 31, 2021; sufficient through Nov 2023.
- Phase 3 RECOVER trial for brilaroxazine enrolled >30% in US; topline data expected mid-2023.
- Announced $8.5M registered direct offering in September 2022.
- Exploring non-dilutive financing for expansion into bipolar, MDD, ADHD, PAH, IPF indications.

## SEC filing metadata
- accession: 0001437749-22-027263
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/0001437749-22-027263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/rvph20221111_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-027263
- JSON: https://secwatch.observer/filing/0001437749-22-027263.json
- Plain text: https://secwatch.observer/filing/0001437749-22-027263.txt

## Key facts
- Earnings Releases
  REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the nine months ended September 30, 2022 results: net income approximately $16.2 million, EPS ($0.87) per share.
  - Period: the nine months ended September 30, 2022
  - Net income: approximately $16.2 million
  - EPS: ($0.87) per share
  - Result: reported results
  source text: The Company reported a net loss of approximately $16.2 million, or ($0.87) per share, for the nine months ended September 30, 2022, compared to a net loss of approximately $4.8 million, or ($0.36) per share, for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/0001437749-22-027263-index.htm
- Earnings Releases
  REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the three months ended September 30, 2022 results: net income approximately $3.5 million, EPS ($0.18) per share.
  - Period: the three months ended September 30, 2022
  - Net income: approximately $3.5 million
  - EPS: ($0.18) per share
  - Result: reported results
  source text: The Company reported a net loss of approximately $3.5 million, or ($0.18) per share, for the three months ended September 30, 2022, compared to a net loss of approximately $2.3 million, or ($0.12) per share, for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/0001437749-22-027263-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.